Antibiotic resistance happens when bacteria evolve to survive the drugs designed to kill them. In 2021, resistant bacterial infections directly caused an estimated 1.14 million deaths worldwide and played a role in 4.71 million more. It’s one of the most pressing threats in modern medicine, and understanding how it works is the first step toward slowing it down.
How Bacteria Become Resistant
Bacteria reproduce rapidly, sometimes dividing every 20 minutes. Each division is a chance for a random genetic mutation. Most mutations do nothing useful, but occasionally one gives a bacterium a way to survive an antibiotic. That bacterium lives, reproduces, and passes the trait to its offspring. The more often bacteria are exposed to antibiotics, the faster this process plays out.
There are four main strategies bacteria use to resist drugs. First, they can block the drug from getting inside, limiting how much actually reaches its target. Second, they can alter the internal structure the drug is supposed to attack. For example, some staph bacteria acquire a gene called mecA that changes the shape of proteins on their cell wall, so certain antibiotics can no longer latch on. Third, bacteria can produce enzymes that break down or chemically disable the drug before it does any damage. A well-known example is the group of enzymes called beta-lactamases, which chew apart penicillin-type antibiotics. Fourth, bacteria can actively pump the drug back out through built-in export channels called efflux pumps, many of which can eject multiple types of drugs at once.
A single bacterium can use more than one of these strategies simultaneously, making it resistant to several antibiotics at the same time. These “multidrug-resistant” organisms are the ones that create the most dangerous clinical situations.
How Resistance Spreads Between Bacteria
What makes antibiotic resistance especially difficult to contain is that bacteria don’t just pass resistance genes to their offspring. They share them sideways, even between completely different species, through a process called horizontal gene transfer. This happens in three main ways.
In conjugation, two bacteria physically connect and one passes a small loop of DNA (a plasmid) carrying resistance genes directly to the other. In transduction, a virus that infects bacteria accidentally packages resistance genes and delivers them to a new bacterial host. In transformation, bacteria pick up free-floating DNA from their environment, often released by dead bacteria nearby. Resistance genes frequently sit on mobile genetic elements like plasmids and transposons, which are essentially portable stretches of DNA built to move. Notably, 11 of the 12 top priority antibiotic-resistant pathogens are known or predicted to be naturally capable of transformation, meaning they can absorb resistance genes straight from their surroundings.
What’s Driving the Problem
Two major forces accelerate resistance: overuse in human medicine and widespread use in agriculture.
In healthcare, antibiotics are frequently prescribed for infections they can’t treat. Colds, the flu, most coughs, bronchitis, many sinus and ear infections, stomach flu, and COVID-19 are all caused by viruses, and antibiotics do nothing against viruses. When you take an antibiotic for a viral illness, it attacks the harmless bacteria living in your body. That unnecessary exposure promotes resistant traits in those otherwise-friendly microbes, which can then share resistance genes with genuinely harmful bacteria or create space for dangerous organisms to move in.
Agriculture is an even larger driver by volume. Roughly 73% of all antibiotics consumed globally go to the meat industry, where they’re used not just to treat sick animals but to promote growth and prevent infections in crowded conditions. Antibiotic residues in livestock select for resistant bacteria in animals’ gut microbiomes. Those resistant bacteria can then reach humans through the food chain, through direct contact with animals, or through water and soil contaminated by agricultural runoff. The environment acts as a reservoir, allowing resistance genes carried on mobile DNA to spread across bacterial populations far beyond the farm.
The Discovery Void
Between 1930 and 1962, researchers developed more than 20 novel classes of antibiotics. Since then, only two new classes have reached the market: one approved in 2000 and another in 2003, both effective only against a subset of bacteria. This means medicine has been relying on variations of the same drug families for over 60 years while bacteria have continued to evolve around them.
The economics of antibiotic development work against progress. New antibiotics are meant to be used sparingly (to slow resistance), which limits sales revenue, making them unattractive investments for pharmaceutical companies compared to drugs patients take daily for chronic conditions. The result is a growing mismatch: bacteria are gaining resistance faster than new treatments arrive.
The Pathogens That Worry Experts Most
The World Health Organization maintains a priority pathogens list, updated in 2024, identifying the bacteria that pose the greatest resistance threat. At the top are gram-negative bacteria resistant to last-resort antibiotics and drug-resistant tuberculosis. Other high-burden threats include resistant strains of Salmonella, Shigella, gonorrhea, Pseudomonas (a common cause of hospital-acquired infections), and Staphylococcus aureus, including the strain known as MRSA.
These organisms are prioritized because they cause common infections, spread easily, and have limited or no remaining treatment options. In the U.S. alone, treating just six of the most alarming resistant threats costs more than $4.6 billion in healthcare spending annually. That figure covers only the direct costs of hospitalization, including medical personnel, equipment, and facilities. It doesn’t account for follow-up care, lost wages, or long-term health consequences, meaning the true economic toll is substantially higher.
How Resistance Is Measured
When you have a bacterial infection and your doctor orders a culture, the lab doesn’t just identify the bacterium. It also tests which antibiotics can still kill it. The standard measurement is called the minimum inhibitory concentration, or MIC: the lowest dose of an antibiotic that completely stops visible bacterial growth in a controlled test.
That number is then compared against established breakpoints, which are thresholds set by international standards organizations. If the MIC falls below the breakpoint, the bacterium is classified as susceptible, meaning standard doses of the antibiotic should work. If it falls above, the bacterium is classified as resistant, meaning treatment with that drug will likely fail even at higher doses. There’s also a middle category where the infection may still respond if the dosing is adjusted or if the drug naturally concentrates at the infection site. This testing process is what determines which antibiotic your doctor prescribes and is the reason why taking a full course matters: stopping early can leave behind the bacteria with the highest tolerance, giving them room to multiply.
What Slows Resistance Down
Antibiotic stewardship is the umbrella term for organized efforts to use antibiotics more carefully. The CDC has developed specific frameworks for hospitals, outpatient clinics, nursing homes, and even resource-limited settings, all aimed at ensuring antibiotics are prescribed only when necessary and at the right dose for the right duration.
On an individual level, the most impactful steps are straightforward. Don’t pressure a doctor for antibiotics when you have a viral illness. If you are prescribed antibiotics, take the full course as directed, even if you feel better partway through. Never share leftover antibiotics or use ones prescribed for someone else. These habits matter because every unnecessary exposure gives bacteria another opportunity to develop resistance.
On a systemic level, reducing agricultural antibiotic use is critical. Several countries have already banned the use of antibiotics as growth promoters in livestock, and the results are encouraging: when antibiotic pressure decreases, resistance rates in animal-associated bacteria tend to drop over time. Investing in new antibiotic development, improving global surveillance of resistant infections, and expanding access to rapid diagnostic testing so doctors can identify infections precisely before prescribing are all pieces of a larger strategy to keep existing antibiotics effective for as long as possible.